SCHEMBL7119418

SCHEMBL7119418

CCOC(=O)c1ccc(N(Cc2ccccc2)c2ccccc2[N+](=O)[O-])cc1C(=O)O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 4/20 0.49
L3MBTL1 Q9Y468 1/20 0.47
ALDH1A1 P00352 6/20 0.43
LMNA P02545 3/20 0.43
MAPT P10636 4/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
MAPK1 P28482 1/20 0.41
GAA P10253 1/20 0.41
KMT2A Q03164 2/20 0.39
TSHR P16473 2/20 0.39
POLB P06746 2/20 0.39
GALR2 O43603 1/20 0.39
MITF O75030 1/20 0.39
HSP90AA1 P07900 1/20 0.39
HPGD P15428 1/20 0.39
XBP1 P17861 1/20 0.39
CCR6 P51684 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
MEN1 O00255 1/20 0.39
ATM Q13315 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7119414 0.85 AR (0.51) ARL3MBTL1ALDH1A1LMNAMAPT
SCHEMBL6933340 0.82 PYGL (0.50) ARALDH1A1MAPTSMN1; SMN2MAPK1
SCHEMBL7198582 0.81 AR (0.46) ARL3MBTL1ALDH1A1MAPTSMN1; SMN2
SCHEMBL8817865 0.75 L3MBTL1 (0.45) ARL3MBTL1ALDH1A1LMNAMAPT
SCHEMBL7116285 0.72 ALDH1A1 (0.47) L3MBTL1ALDH1A1LMNAMAPTSMN1; SMN2
SCHEMBL6169177 0.71 MAPT (0.50) ARALDH1A1LMNAMAPTSMN1; SMN2
SCHEMBL7319630 0.71 ALDH1A1 (0.47) ARL3MBTL1ALDH1A1LMNAMAPT
SCHEMBL7116626 0.70 SMN1; SMN2 (0.64) ALDH1A1MAPTSMN1; SMN2GAAKMT2A
SCHEMBL11669017 0.70 TSHR (0.51) L3MBTL1ALDH1A1LMNAMAPTSMN1; SMN2
SCHEMBL1523174 0.70 ALDH1A1 (0.67) L3MBTL1ALDH1A1LMNAMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030186944-A1 Such as 4-(2-(3-dimethylaminobenzoylamino)phenoxy)phthalic acid for treatment/prevention of diabetes; for inhibiting liver glycogen phosphorylase; dietetics KRISTIANSEN MARIT (DK) 2003-10-02 US disclosed
US-6590118-B1 Used in treatment of and/or prevention of diabetes, especially non-insulin dependent diabetes (Type 2 diabetes) NOVO NORDISK A/S (DK) 2003-07-08 US disclosed
EP-1220832-A1 NOVEL AROMATIC COMPOUNDS NOVO NORDISK A/S (DK) 2002-07-10 EP disclosed
WO-2001023347-A1 NOVEL AROMATIC COMPOUNDS NOVO NORDISK A/S (DK) 2001-04-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030186944-A1 Such as 4-(2-(3-dimethylaminobenzoylamino)phenoxy)phthalic acid for treatment/prevention of diabetes; for inhibiting liver glycogen phosphorylase; dietetics PYGL, GYS2, PYGM AR 3826/4885L3MBTL1 2231/4885ALDH1A1 901/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.